Lantern Pharma Inc Financials
Financial Health Signals
Lantern Pharma Inc passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
For every $1 of reported earnings, Lantern Pharma Inc generates $0.86 in operating cash flow (-$17.8M OCF vs -$20.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
This page shows Lantern Pharma Inc (LTRN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Lantern Pharma Inc's EBITDA was -$22.2M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 24.3% from the prior year.
Lantern Pharma Inc generated -$17.8M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 24.1% from the prior year.
Lantern Pharma Inc reported -$20.8M in net income in fiscal year 2024. This represents a decrease of 30.2% from the prior year.
Lantern Pharma Inc earned $-1.93 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 31.3% from the prior year.
Lantern Pharma Inc held $7.5M in cash against $0 in long-term debt as of fiscal year 2024.
Lantern Pharma Inc had 11M shares outstanding in fiscal year 2024. This represents an increase of 0.6% from the prior year.
Lantern Pharma Inc invested $16.1M in research and development in fiscal year 2024. This represents an increase of 35.6% from the prior year.
Lantern Pharma Inc invested $13K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 32.8% from the prior year.
LTRN Income Statement
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $2.4M-34.4% | $3.7M | N/A | $2.2M | N/A | $702K | N/A | $3.0M |
| SG&A Expenses | $1.9M+30.8% | $1.5M | N/A | $1.3M | N/A | $1.4M | N/A | $1.2M |
| Operating Income | -$4.3M+16.0% | -$5.2M | N/A | -$3.5M | N/A | -$2.1M | N/A | -$4.1M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$4.2M+7.3% | -$4.5M | N/A | -$3.2M | N/A | -$2.3M | N/A | -$4.1M |
| EPS (Diluted) | $-0.39+7.1% | $-0.42 | N/A | $-0.29 | N/A | $-0.21 | N/A | N/A |
LTRN Balance Sheet
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $13.6M-46.7% | $25.6M-41.4% | $43.6M-8.6% | $47.8M-18.8% | $58.8M-5.4% | $62.2M-15.9% | $74.0M-4.7% | $77.6M |
| Current Assets | $13.5M-46.7% | $25.2M-41.7% | $43.3M-8.6% | $47.4M-19.2% | $58.7M-5.3% | $62.0M-14.7% | $72.7M-4.7% | $76.3M |
| Cash & Equivalents | $8.4M+11.7% | $7.5M-65.8% | $21.9M-14.2% | $25.6M-31.3% | $37.2M-5.2% | $39.3M-23.8% | $51.5M-5.8% | $54.7M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $4.0M-7.8% | $4.4M+60.0% | $2.7M+16.1% | $2.4M-15.7% | $2.8M-10.9% | $3.1M+31.9% | $2.4M+26.7% | $1.9M |
| Current Liabilities | $4.0M-6.7% | $4.3M+61.7% | $2.7M+18.9% | $2.3M-19.5% | $2.8M-10.9% | $3.1M+34.9% | $2.3M+30.3% | $1.8M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $9.6M-54.8% | $21.2M-48.2% | $40.9M-9.9% | $45.4M-19.0% | $56.0M-5.1% | $59.0M-17.5% | $71.6M-5.5% | $75.7M |
| Retained Earnings | -$89.1M-17.2% | -$76.0M-37.6% | -$55.2M-8.2% | -$51.1M-30.0% | -$39.3M-9.4% | -$35.9M-43.5% | -$25.0M-16.5% | -$21.5M |
LTRN Cash Flow Statement
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$4.6M-15.1% | -$4.0M-17.3% | -$3.4M+6.3% | -$3.6M-35.3% | -$2.7M+33.9% | -$4.0M-98.0% | -$2.0M+56.5% | -$4.7M |
| Capital Expenditures | $555-82.0% | $3K-39.3% | $5K+6.4% | $5K-31.3% | $7K+3.6% | $7K+671000.0% | $1-100.0% | $3K |
| Free Cash Flow | -$4.6M-15.0% | -$4.0M-17.2% | -$3.4M+6.3% | -$3.6M-35.2% | -$2.7M+33.8% | -$4.0M-98.4% | -$2.0M+56.5% | -$4.7M |
| Investing Cash Flow | $5.9M+72.0% | $3.4M+1245.6% | $256K+10.6% | $232K-61.6% | $603K+910.7% | -$74K+68.2% | -$234K+76.7% | -$1.0M |
| Financing Cash Flow | N/A | $0 | N/A | N/A | $0 | $0+100.0% | -$873K | $0 |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | $0 | $0 | N/A | N/A |
LTRN Financial Ratios
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -30.7%-15.8pp | -14.9% | N/A | -6.6% | N/A | -3.6% | N/A | -5.2% |
| Current Ratio | 3.33-2.5 | 5.83-10.4 | 16.18-4.9 | 21.05+0.1 | 20.99+1.2 | 19.76-11.5 | 31.26-11.5 | 42.75 |
| Debt-to-Equity | 0.42+0.2 | 0.21+0.1 | 0.07+0.0 | 0.050.0 | 0.050.0 | 0.05+0.0 | 0.030.0 | 0.02 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Lantern Pharma Inc profitable?
No, Lantern Pharma Inc (LTRN) reported a net income of -$20.8M in fiscal year 2024.
What is Lantern Pharma Inc's earnings per share (EPS)?
Lantern Pharma Inc (LTRN) reported diluted earnings per share of $-1.93 for fiscal year 2024. This represents a -31.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Lantern Pharma Inc's EBITDA?
Lantern Pharma Inc (LTRN) had EBITDA of -$22.2M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Lantern Pharma Inc's free cash flow?
Lantern Pharma Inc (LTRN) generated -$17.8M in free cash flow during fiscal year 2024. This represents a -24.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Lantern Pharma Inc's operating cash flow?
Lantern Pharma Inc (LTRN) generated -$17.8M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Lantern Pharma Inc's total assets?
Lantern Pharma Inc (LTRN) had $25.6M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Lantern Pharma Inc's capital expenditures?
Lantern Pharma Inc (LTRN) invested $13K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Lantern Pharma Inc spend on research and development?
Lantern Pharma Inc (LTRN) invested $16.1M in research and development during fiscal year 2024.
How many shares does Lantern Pharma Inc have outstanding?
Lantern Pharma Inc (LTRN) had 11M shares outstanding as of fiscal year 2024.
What is Lantern Pharma Inc's current ratio?
Lantern Pharma Inc (LTRN) had a current ratio of 5.83 as of fiscal year 2024, which is generally considered healthy.
What is Lantern Pharma Inc's debt-to-equity ratio?
Lantern Pharma Inc (LTRN) had a debt-to-equity ratio of 0.21 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Lantern Pharma Inc's return on assets (ROA)?
Lantern Pharma Inc (LTRN) had a return on assets of -81.3% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Lantern Pharma Inc's cash runway?
Based on fiscal year 2024 data, Lantern Pharma Inc (LTRN) had $7.5M in cash against an annual operating cash burn of $17.8M. This gives an estimated cash runway of approximately 5 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Lantern Pharma Inc's Piotroski F-Score?
Lantern Pharma Inc (LTRN) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Lantern Pharma Inc's earnings high quality?
Lantern Pharma Inc (LTRN) has an earnings quality ratio of 0.86x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.